NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)

INTRODUCTION: Poorly differentiated (PD), extrapulmonary (EP), neuroendocrine carcinomas (NECs) are rare but aggressive neuroendocrine neoplasms. First-line treatment for advanced disease is an etoposide and platinum-based chemotherapy combination. There is no established second-line treatment for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Craig, Zoe, Swain, Jayne, Batman, Emma, Wadsley, Jonathan, Reed, Nicholas, Faluyi, Olusola, Cave, Judith, Sharma, Rohini, Chau, Ian, Wall, Lucy, Lamarca, Angela, Hubner, R, Mansoor, Wasat, Sarker, Debashis, Meyer, Tim, Cairns, David A, Howard, Helen, Valle, Juan W, McNamara, Mairéad G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045240/
https://www.ncbi.nlm.nih.gov/pubmed/32029495
http://dx.doi.org/10.1136/bmjopen-2019-034527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045240/
https://www.ncbi.nlm.nih.gov/pubmed/32029495
http://dx.doi.org/10.1136/bmjopen-2019-034527

Ejemplares similares